Company
Every investor coverage indicates participated in a round Clinical Genomics raised.
Investors whose own portfolio pages list Clinical Genomics, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| MA Financial Group | its portfolio page ↗ |
| MA Growth Ventures | its portfolio page ↗ |
Companies Clinical Genomics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Lawrence LaPointe | President and CEO | einpresswire.com |
Stories naming Clinical Genomics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.
Diagnostics company Clinical Genomics closed a $15m Series A led by Sydney VC OneVentures to commercialise its blood test for monitoring bowel cancer recurrence; OneVentures partner Dr Paul Kelly joins its board.